Growth-hormone response to clonidine in panic disorder patients in comparison to patients with major depression and healthy controls.
Growth-hormone (GH) responses to the alpha 2-adrenoceptor agonist clonidine were measured in 9 panic disorder patients, in 9 patients fulfilling DSM-III-R criteria for major depressive episode, and in 9 age- and sex-matched controls. GH responses to clonidine were not significantly different between the groups. The data do not agree with the assumption that blunted GH responses to clonidine represent a general feature of panic disorder or major depression.
Gann
H
H
Department of Psychiatry, Central Institute of Mental Health, Mannheim, Germany.
Riemann
D
D
Stoll
S
S
Berger
M
M
Müller
W E
WE
D000316:Adrenergic alpha-Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D003000:Clonidine / Q000009:adverse effects* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000097:blood* / Q000188:drug therapy / Q000523:psychology; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000097:blood* / Q000188:drug therapy / Q000523:psychology; D011569:Psychiatric Status Rating Scales
D000316:Adrenergic alpha-Agonists; D013006:Growth Hormone; D003000:Clonidine